Radiopharmaceutical NET therapy with 43% ORR now entering Phase 3 prep — regulatory alignment is the gate

Perspective Therapeutics is a clinical-stage company developing a radiopharmaceutical therapy for neuroendocrine tumors that is not yet approved.

Perspective Therapeutics is building a lead-212 targeted alpha therapy platform, with VMT-NET producing a 43% objective response rate and deepening, durable disease control across 68 SSTR2-positive neuroendocrine tumor patients. The thesis resolves on whether FDA aligns on a registrational pathway from Phase 1/2a data alone, without a full randomized Phase 3 primary endpoint. Runway into late 2027 covers Phase 3 site activation but not trial completion, making a financing event likely before pivotal data matures.